Results 41 to 50 of about 31,034 (262)
Treatment of dry age-related macular degeneration with dobesilate [PDF]
BMJ Case Reports, 2012 The authors present anatomical and functional evidences of dry age-macular degeneration improvement, after intravitreal treatment with dobesilate. Main outcomes measures were normalisation of retinal structure and function, assessed by optical coherence tomography, fundus-monitored microperimetry, electrophysiology and visual acuity.
P, Cuevas +3 more
openaire +2 more sources
Targeting the Complement Cascade for Treatment of Dry Age-Related Macular Degeneration
Biomedicines, 2022 Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in the elderly population. AMD is characterized in its late form by neovascularization (wet type) or geographic atrophy of the retinal pigment epithelium cell layer ...
Prem N. Patel +5 more
doaj +1 more source
In Vivo Multimodal Imaging of Drusenoid Lesions in Rhesus Macaques. [PDF]
, 2017 Nonhuman primates are the only mammals to possess a true macula similar to humans, and spontaneously develop drusenoid lesions which are hallmarks of age-related macular degeneration (AMD).
Cunefare, David +8 more
core +2 more sources
Overview of clinical trials for dry age-related macular degeneration
Journal of Medical Sciences, 2017 The overall goal of treating age-related macular degeneration (AMD) is to target the underlying cause of the disease and prevent, or at least slow down, the loss of vision, which requires the preservation of the choroid, retinal pigment epithelium (RPE),
Wen-Sheng Cheng +3 more
doaj +1 more source
Photo-damage, photo-protection and age-related macular degeneration [PDF]
, 2015 Age-related macular degeneration (AMD) is a degenerative retinal disease that causes blindness in people 60-65 years and older, with the highest prevalence appearing in people 90 years-old or more.
Marquioni Ramella, Melisa Daniela +1 more
core +1 more source
Journal of Ophthalmology, 2021 Background: The chronic ischemic process caused by impaired hemodynamics in the eye and brain is a component of the pathogenesis of ischemic optic neuropathy and age-related macular degeneration, and requires prompt and adequate treatment. Purpose: To
V. S. Ponomarchuk +2 more
doaj +1 more source
Dry Age Related Macular Degeneration – Oral Supplements, Which Combination and When ?
Delhi Journal of Ophthalmology, 2018 Age related macular degeneration (AMD), a leading cause of visual loss in the elderly, is emerging as an important public health problem due to the increase in the ageing population. Dry AMD which is the more prevalent form has no effective treatment and
T. Lekha
doaj +1 more source
Ophthalmic community perception of new medication needs [PDF]
International Journal of Ophthalmology, 2018 AIM: To survey ophthalmologists (who have participated previously in clinical research) and ophthalmic industry professionals (who have been involved in ocular research and development) to indicate perceived needs for new pharmaceuticals in various ...
William C. Stewart +2 more
doaj +1 more source
Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. [PDF]
, 2020 AimTo show the characteristics and outcomes of patients with neovascular age-related macular degeneration (nAMD) who had extended remission (ER) while on a pro re nata (PRN) treatment protocol.MethodsThis was a retrospective case-control study of a ...
Amador-Patarroyo, Manuel J +6 more
core
Dry Age-Related Macular Degeneration
, 2020 Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world in people over 50 years of age (Gehrs et al. 2006). Worldwide, age-related macular degeneration is projected to affect around 196 million people by 2020, increasing to 288 million in 2040 (Wong et al. 2014).
Vikram S. Makhijani +2 more
openaire +1 more source